MedTrace Logo

The Role of Follicle Stimulating Hormone in Advanced Prostate Cancer

NCT04134130 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 33

Last updated 2020-01-22

No results posted yet for this study

Summary

In order to elucidate if FSH can have testosterone like effects, samples from young, non-smoking healthy volunteers, with normal body mass index, and with pharmacologically induced gonadotropin deficiency will be studied regarding their capacity to induce prostate specific antigen (PSA), which normally is regulated by testosterone.

Conditions

  • Prostate Cancer Recurrent

Interventions

DRUG

Degarelix 120 MG [Firmagon]

Two doses of degarelix, 240 mg, subcutaneously once, at study start.

DRUG

Gonal F RFF Pen 900 UNT Per 1.5 ML Pen Injector

Gonal-f 300 IU subcutaneously 3 times per week for 5 weeks.

DRUG

Testosterone Undecanoate

One dose 1000 mg testosterone once, after 3 weeks.

Sponsors & Collaborators

  • Swedish Cancer Foundation

    collaborator OTHER

  • ALF Swedish Government Grant

    collaborator UNKNOWN

  • Lund University

    lead OTHER

Principal Investigators

  • Yvonne Lundberg Giwercman, Professor · Lund University, dept Translational medicine

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
30 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-09-16
Primary Completion
2019-12-20
Completion
2019-12-31

Countries

  • Sweden

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04134130 on ClinicalTrials.gov